MX2023004998A - Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. - Google Patents
Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.Info
- Publication number
- MX2023004998A MX2023004998A MX2023004998A MX2023004998A MX2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A MX 2023004998 A MX2023004998 A MX 2023004998A
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancers
- quinazoline derivatives
- substituted quinazoline
- alkyne substituted
- compound
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 125000002355 alkine group Chemical group 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037844 advanced solid tumor Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se refiere a métodos para tratar o prevenir el cáncer (p. ej., cáncer sólido avanzado) mediante el uso del Compuesto núm. 1 o el Compuesto núm. 2: (ver Fórmula) (Compuesto núm. 1) (ver Fórmula) (Compuesto núm. 2) o una sal farmacéuticamente aceptable de estos. La presente descripción también se refiere a composiciones farmacéuticas y kits farmacéuticos adecuados para el tratamiento o la prevención.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108645P | 2020-11-02 | 2020-11-02 | |
| US202163166045P | 2021-03-25 | 2021-03-25 | |
| US202163190067P | 2021-05-18 | 2021-05-18 | |
| US202163218717P | 2021-07-06 | 2021-07-06 | |
| US202163237782P | 2021-08-27 | 2021-08-27 | |
| US202163244540P | 2021-09-15 | 2021-09-15 | |
| PCT/US2021/057724 WO2022094464A1 (en) | 2020-11-02 | 2021-11-02 | Method of treating cancers with alkyne substituted quinazoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004998A true MX2023004998A (es) | 2023-05-12 |
Family
ID=78819639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004998A MX2023004998A (es) | 2020-11-02 | 2021-11-02 | Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240075042A1 (es) |
| EP (1) | EP4236954A1 (es) |
| JP (1) | JP2023548055A (es) |
| KR (1) | KR20230093429A (es) |
| AU (1) | AU2021368798A1 (es) |
| CA (1) | CA3195473A1 (es) |
| IL (1) | IL302329A (es) |
| MX (1) | MX2023004998A (es) |
| TW (1) | TW202235083A (es) |
| WO (1) | WO2022094464A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114787150A (zh) | 2019-08-15 | 2022-07-22 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| MX2024003475A (es) * | 2021-09-21 | 2024-04-05 | Black Diamond Therapeutics Inc | Polimorfos como inhibidores de erbb. |
| WO2025038731A1 (en) * | 2023-08-15 | 2025-02-20 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| WO2025128831A1 (en) * | 2023-12-13 | 2025-06-19 | Black Diamond Therapeutics, Inc. | Combinations comprising alkyne substituted quinazoline derivatives and their use in the treatment of cancer |
| WO2025137421A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Compositions comprising alkyne substituted quinazoline derivatives and related uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200003933A (ko) * | 2011-03-04 | 2020-01-10 | 뉴젠 세러퓨틱스 인코포레이티드 | 알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법 |
| WO2016105582A1 (en) * | 2014-12-24 | 2016-06-30 | Nunn Philip A | Compositions for ileo-jejunal drug delivery |
| CN113382986A (zh) * | 2018-09-25 | 2021-09-10 | 黑钻治疗公司 | 酪氨酸激酶抑制剂组合物、其制备方法和使用方法 |
| CN114787150A (zh) * | 2019-08-15 | 2022-07-22 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
-
2021
- 2021-11-02 TW TW110140833A patent/TW202235083A/zh unknown
- 2021-11-02 WO PCT/US2021/057724 patent/WO2022094464A1/en not_active Ceased
- 2021-11-02 KR KR1020237013278A patent/KR20230093429A/ko active Pending
- 2021-11-02 EP EP21816235.2A patent/EP4236954A1/en active Pending
- 2021-11-02 CA CA3195473A patent/CA3195473A1/en active Pending
- 2021-11-02 IL IL302329A patent/IL302329A/en unknown
- 2021-11-02 AU AU2021368798A patent/AU2021368798A1/en active Pending
- 2021-11-02 US US18/034,749 patent/US20240075042A1/en active Pending
- 2021-11-02 JP JP2023524708A patent/JP2023548055A/ja active Pending
- 2021-11-02 MX MX2023004998A patent/MX2023004998A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3195473A1 (en) | 2022-05-05 |
| KR20230093429A (ko) | 2023-06-27 |
| TW202235083A (zh) | 2022-09-16 |
| US20240075042A1 (en) | 2024-03-07 |
| AU2021368798A9 (en) | 2023-07-06 |
| EP4236954A1 (en) | 2023-09-06 |
| JP2023548055A (ja) | 2023-11-15 |
| AU2021368798A1 (en) | 2023-05-18 |
| IL302329A (en) | 2023-06-01 |
| WO2022094464A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004998A (es) | Metodo para tratar canceres con derivados de quinazolina sustituida con alquino. | |
| MX2022002415A (es) | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| PH12021551274A1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors | |
| MX2023010411A (es) | Inhibidores de erbb/btk. | |
| MX2023012060A (es) | Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr. | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| MX2024000299A (es) | Compuestos antivirales. | |
| MX2023007058A (es) | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. | |
| PH12022553389A1 (en) | Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia | |
| MX2023006883A (es) | Metodos para tratar el cancer de prostata. | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MX2022014192A (es) | Metodos para tratar el cancer de prostata. | |
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| CA3252219A1 (en) | THIOStrepton-inspired compounds for cancer treatment and related preparations | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| ZA202308282B (en) | Toxin molecule suitable for antibody-drug conjugate | |
| MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| EP4364807A3 (en) | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder | |
| WO2025019819A3 (en) | Small molecule protein degraders of kras g12d mutant | |
| MX2023001275A (es) | Inhibidores de raf biciclicos fusionados y metodos para su uso. | |
| MX2025004409A (es) | Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. |